Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598706 | 0.83 | DRD2 (0.74) | DRD2KCNH2DRD3OPRM1HTR7 | |
| SCHEMBL12879718 | 0.82 | KCNH2 (0.74) | DRD2KCNH2ALDH1A1MAPTHTR7 | |
| SCHEMBL5430857 | 0.82 | L3MBTL1 (0.53) | DRD2KCNH2MAPTTSHRSMN1; SMN2 | |
| SCHEMBL7289093 | 0.82 | KCNH2 (0.74) | HTR1AKCNH2HTR7 | |
| SCHEMBL9537160 | 0.82 | DRD2 (0.51) | DRD2HTR1AKCNH2DRD3OPRM1 | |
| SCHEMBL6942579 | 0.82 | ADRA2C (0.80) | ADRA2CHTR1AALDH1A1CYP3A4MAPT | |
| SCHEMBL3230486 | 0.81 | HTR7 (0.59) | DRD2HTR1AKCNH2ALDH1A1MAPT | |
| SCHEMBL6150880 | 0.81 | MAPT (0.62) | ADRA2CDRD2HTR1AKCNH2CYP2D6 | |
| SCHEMBL6151437 | 0.81 | MAPT (0.62) | ADRA2CDRD2HTR1AKCNH2CYP2D6 | |
| SCHEMBL188852 | 0.81 | MAPT (0.62) | ADRA2CDRD2HTR1AKCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022157166-A1 | THIAZOLOPYRIMIDONES AS INHIBITORS OF DDR1/2 AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022157166-A1 | THIAZOLOPYRIMIDONES AS INHIBITORS OF DDR1/2 AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-07-28 | — | — | WO | disclosed |
| EP-4032896-A1 | THIAZOLOPYRIMIDONES AS INHIBITORS OF DDR1/2 AND THERAPEUTIC USES THEREOF | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-07-27 | — | — | EP | disclosed |
| EP-3514153-B1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HANMI PHARM IND CO LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3789386-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2021-03-10 | — | — | EP | disclosed |
| EP-3212652-B1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2021-02-17 | — | — | EP | disclosed |
| EP-3212652-B1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2021-02-17 | — | — | EP | disclosed |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-29 | — | — | US | disclosed |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-29 | — | — | US | disclosed |
| CN-107454899-B | RIPK2 inhibitors and methods of treating cancer therewith | 大学健康网络 | 2020-05-29 | — | — | CN | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6710044-B2 | Technical field | NEUROSEARCH A/S (DK) | 2004-03-23 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | NEUROSEARCH A/S | 2003-09-04 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0934281-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA- A? RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017651-A1 | 1-PHENYL-BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS BAGA-A RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166638-A1 | Benzimidazole's used as aminobutyric acid receptor modulators, for prophylaxis of nervous system disorders such as anxiety, sleep disorders, epilepsia or convulsions | GABRA1, GABRA2, GABRA4 | ADRA2C 82/4885DRD2 488/4885HTR1A 123/4885 |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ADRA2C 40/4885DRD2 1816/4885HTR1A 1344/4885 |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | RIPK2, RIPK1, RIPK4 | ADRA2C 4753/4885DRD2 4558/4885HTR1A 4757/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ADRA2C 39/4885DRD2 1504/4885HTR1A 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.